- Home
- RMM vs RCEL Comparison
RMM vs RCEL Comparison
Compare RMM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- RCEL
- Stock Information
- Founded
- RMM 2019
- RCEL 2020
- Country
- RMM United States
- RCEL United States
- Employees
- RMM N/A
- RCEL N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- RCEL Medical/Dental Instruments
- Sector
- RMM Finance
- RCEL Health Care
- Exchange
- RMM Nasdaq
- RCEL Nasdaq
- Market Cap
- RMM 292.7M
- RCEL 308.6M
- IPO Year
- RMM N/A
- RCEL N/A
- Fundamental
- Price
- RMM $14.84
- RCEL $8.68
- Analyst Decision
- RMM
- RCEL Buy
- Analyst Count
- RMM 0
- RCEL 5
- Target Price
- RMM N/A
- RCEL $18.00
- AVG Volume (30 Days)
- RMM 66.5K
- RCEL 251.2K
- Earning Date
- RMM 01-01-0001
- RCEL 02-13-2025
- Dividend Yield
- RMM 7.33%
- RCEL N/A
- EPS Growth
- RMM N/A
- RCEL N/A
- EPS
- RMM 0.96
- RCEL N/A
- Revenue
- RMM N/A
- RCEL $60,040,000.00
- Revenue This Year
- RMM N/A
- RCEL $36.71
- Revenue Next Year
- RMM N/A
- RCEL $54.48
- P/E Ratio
- RMM $15.55
- RCEL N/A
- Revenue Growth
- RMM N/A
- RCEL 32.24
- 52 Week Low
- RMM $12.32
- RCEL $7.51
- 52 Week High
- RMM $16.10
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- RMM 50.96
- RCEL 31.57
- Support Level
- RMM $14.67
- RCEL $8.53
- Resistance Level
- RMM $14.91
- RCEL $8.92
- Average True Range (ATR)
- RMM 0.13
- RCEL 0.62
- MACD
- RMM 0.06
- RCEL -0.33
- Stochastic Oscillator
- RMM 92.19
- RCEL 3.10
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.